5002572026-04-012026-06-305002572026-04-012026-06-30in-capmkt:OtherExpenses1Member5002572026-04-012026-06-30in-capmkt:OtherExpenses2Member5002572026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2026-04-012027-03-312026-08-062026-07-22INRMillionsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-08-0616:30:002026-08-0621:40:00Not applicablefalsefalseThe disclosure for the default on Loans and Debt Securities is not applicable to the Company.2026-04-012026-06-30UnauditedStandalone71719000000102480000072743800000105055000003089000000-996000007196900000355600000190010000013695700000366432000003610060000003610060000089257000002890000089546000000271460000000000271460000007060000027216600000914500000259.3759.270059.3759.271. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. <br /> 2. During the quarter ended June 30, 2026, 53,425 equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up equity share capital by Rs. 0.1 million and securities premium account by Rs. 76.9 million. <br /> 3. Exceptional items <br /> a. The Company and its subsidiary are exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and a possible violation of federal and state antitrust laws.These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the year ended March 31 2026, the Company on best estimate recorded a provision of Rs. 4,493.9 million (USD 50.0 million) towards this litigation without admission of liability or wrongdoing. During the quarter ended March 31, 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. In April 2026, the wholly owned subsidiary settled one of the ongoing dispute for an amount of Rs. 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. <br /> b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets and agreed to pay USD 90.0 million. During the year ended March 31, 2026, the Company has compensated Lupin Pharmaceuticals, Inc., U.S.A., for the settlement payment of Rs. 1,364.7 million (USD 15.0 million) made by it and accordingly expensed. The balance amount of USD 75.0 million towards prepaid option has been paid and capitalised by the subsidiary. <br /> c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 496.4 million during the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <br /> d. During the year ended March 31, 2026, the Company has transferred its Over the Counter ('OTC') and API R&D business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concern on slump sale basis for a consideration of Rs. 8,200.0 million and Rs. 180.0 million resulting in gain on divestment of Rs. 6,589.6 million and Rs. 37.2 million respectively. <br /> e. During the year ended March 31, 2026, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 700.0 million. <br /> 4. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2025.The year-to-date figures up to the third quarter ended December 31, 2025 were only subject to Limited Review and not audited.Other expenses13619900000Net loss / (gain) on foreign currency transactions75800000Remeasurements of Defined Benefit Liability-800000-800000-300000The effective portion of gain & losses on hedging instruments in a cash flow hedge1092000001092000003810000070600000